Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Lilly

Apple, Nvidia, and more of the 2025 World's Most Admired Companies

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

Fortune

What Does the Future Hold for Eli Lilly?

Eli Lilly's two major GLP-1 drugs have dominated headlines, but a slate of new treatments in development—and some already available—suggest a bright future.

MarketBeat

The Misty Isle’s magic: Feasting my way around the Isle of Skye

TOP TABLES: What happens when a food writer swaps London’s bustle for Scotland’s beauty? Lilly Subbotin discovers the unexpected culinary delights of Skye – from langoustines on a harbour boat to black garlic butter that tastes like witchcraft

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

How we diagnose and define obesity is set to change – here’s why, and what it means for treatment

Obesity is linked to many common diseases, such as type 2 diabetes, heart disease, fatty liver disease and knee osteoarthritis.

The Conversation

Eli Lilly: 4 Reasons Investors Shouldn’t Miss This Opportunity

Eli Lilly shares are down 17.7% from its highs. The company posted 128% YoY revenue jump in its Mounjaro GLP-1/GIP treatment with no signs of slowing down.

MarketBeat

Eli Lilly's Q4 2024 Earnings: What to Expect

Eli Lilly is scheduled to release its Q4 earnings report next month, and analysts forecast triple-digit profit growth.

Barchart

Elon Musk Weighs In on Weight-Loss Drug Stocks. Is LLY or NVO a Better Buy?

Elon Musk’s preference for Eli Lilly’s Mounjaro over Novo Nordisk’s Ozempic has sparked increased interest in weight-loss drug stocks.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Is Eli Lilly Stock a Buy, Sell, or Hold for 2025?

Eli Lilly is very close to joining the $1 trillion club. Should you buy shares now?

Barchart

3 Big-Name Stocks Just Announced Big-Time Dividend Increases

Eli Lilly, plus two other massive companies, just announced double-digit percentage increases in their quarterly dividend payments.

MarketBeat

FDA says knockoff versions of Lilly obesity drug must come off the market

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes

The Independent UK

Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

MarketBeat

Eli Lilly To Invest $3B To Expand Plant To Meet Surge In Demand For Weight Loss Drugs

Construction on the facility in Kenosha County, Wis., is expected to begin next year.

International Business Times

Eli Lilly Invests Billion In Manufacturing Expansion Projects

Eli Lilly invests billion to boost manufacturing capabilities, expanding in Wisconsin and Indianapolis to meet growing market demand.

Top News

Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound

Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Is Zepbound or Wegovy better for weight loss? New clinical trial reveals which medication sheds more pounds

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables.

Benzinga

Decoding Eli Lilly's Options Activity: What's the Big Picture?

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly (NYSE:LLY).

Barchart

3 Mega-Cap Stocks to Buy Before They're Worth $1 Trillion

These corporate giants could be the next entrants to the $1 trillion market cap club.

Benzinga

Behind the Scenes of Eli Lilly's Latest Options Trends

Financial giants have made a conspicuous bearish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:LLY) revealed 8 unusual trades.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert

STOCK RISES OVER 2.8% AT ITS HIGH FOR THE DAY

Barchart

2 Vaccine Stocks to Buy on the Dip

Given the cutting-edge pipeline for these two vaccine companies, double-digit slumps in these stocks present a compelling entry point for investors.

International Business Times

Weight-Loss Drugmakers Press Companies To Cover Cost Of Treatment

The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 billion a year.

International Business Times

Lilly Sues US Agency For Blocking Proposed Drug Rebate Plan

Eli Lilly is taking the HRSA to court for allegedly blocking the pharma's discount plan.

Fortune

Eli Lilly CEO's explains how failing fast leads to success

For Eli Lilly CEO Dave Ricks, speeding up the drug discovery process is essential to success.

Barchart

Eli Lilly Stock: Is Wall Street Bullish or Bearish?

Eli Lilly has outperformed the broader market and its peers this year, and Wall Street analysts are bullish about the stock’s prospects.

The Guardian - UK

Approved weight-loss drug contributed to UK nurse’s death, report says

Susan McGowan took two doses of tirzepatide, under Mounjaro brand, before she died in North Lanarkshire

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.